Apyx Medical Corporation

Equities

APYX

US03837C1062

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 11:04:31 2024-04-16 am EDT 5-day change 1st Jan Change
1.365 USD -1.09% Intraday chart for Apyx Medical Corporation -9.86% -49.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Apyx Medical Corporation, Q4 2023 Earnings Call, Mar 21, 2024
Apyx Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024 CI
Apyx Medical Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body CI
Apyx Medical Reports Q4, Full-Year 2023 Preliminary Revenue MT
Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Apyx Medical Names Matthew Hill as CFO MT
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023 CI
Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer CI
Stephens Adjusts Price Target on Apyx Medical to $5 From $8, Keeps Overweight Rating MT
Transcript : Apyx Medical Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (APYX) APYX MEDICAL CORPORATION Posts Q3 Revenue $12M, vs. Street Est of $15.4M MT
Apyx Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors CI
Apyx Medical Corporation Revises Earnings Guidance for the Year 2023 CI
Apyx Medical Corporation announced that it expects to receive $45 million in funding CI
Transcript : Apyx Medical Corporation, Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (APYX) APYX MEDICAL CORPORATION Reports Q2 Revenue $13.6M, vs. Street Est of $14.3M MT
Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023 CI
Apyx Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Stephens Initiates Apyx Medical With Overweight Rating, $8 Price Target MT
Insider Sell: Apyx Medical MT
Lake Street Raises Apyx Medical's Price Target to $9 From $6, Maintains Buy Rating MT
Chart Apyx Medical Corporation
More charts
Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.38 USD
Average target price
3.625 USD
Spread / Average Target
+162.68%
Consensus